肝硬化门脉高压症并发血栓形成机制和治疗研究进展*

doi:10.3969/j.issn.1672-5069.2019.06.039

摘要/Abstract

摘要： 肝硬化门脉高压症并发血栓是临床研究实践过程中面临的难题。本文通过对其形成机制和治疗相关研究进展进行总结,重点介绍了近年来国内外关于肝硬化门脉高压并发门脉血栓发生机制和治疗进展。目前认识的主要发生机制包括肝星状细胞的活性、内皮细胞的功能、机体促凝血和凝血抑制失衡等,治疗措施包括低分子肝素等抗凝治疗、β受体阻滞剂和其他药物,如辛伐他汀、利福昔明和益生菌等联合应用以降低门脉压力治疗、提高一氧化氮合成酶磷酸化水平和针对线粒体的抗氧化治疗等措施。

关键词: 门脉高压, 门脉血栓, 发病机制, 治疗

Abstract: The portal thrombosis in cirrhotic patients with portal hypertension is a difficult problem in clinical practice. In this review,we made a summary about studies related on its pathological mechanism and treatment of portal vein thrombosis in patients with portal hypertension. At present,the mechanisms are mainly involving the activities of hepatic stellate cells,endothelial cell functions and the imbalance between pro-coagulation and anticoagulation. For the treatment,it consists of anticoagulant therapy,such as low molecular weight heparin,reducing portal vein pressure,like the combination of β-blockers with other medicines,simvastatin,rifaximin and probiotics,for instance,the increase of eNOS phosphorylation,and antioxidant therapy for mitochondria.

Key words: Portal hypertension, Portal thrombosis, Mechanism, Treatment

张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.

Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment[J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.

参考文献

[1] Loffredo L,Pastori D,Farcomeni A,et al.Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:a systematic review and Meta-analysis. Gastroenterology,2017,153(2):480-487.
[2] Fernandez M.Molecular pathophysiology of portal hypertension. Hepatology,2015,61(4):1406-1415.
[3] Gaca MD,Zhou X,Benyon RC.Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol,2002,36(3):362-369.
[4] Rockey DC,Chung JJ.Reduced nitric oxide production by endothelial cells in cirrhotic rat liver:endothelial dysfunction in portal hypertension. Gastroenterology,1998,114(2):344-351.
[5] Zeng XQ,Li N,Pan DY,et al.Kruppel-like factor 2 inhibit the angiogenesis of cultured human liver sinusoidal endothelial cells through the ERK1/2 signaling pathway.Biochem Biophys Res Commun,2015,464(4):1241-1247.
[6] Tripathi D,Hayes PC.Beta-blockers in portal hypertension: new developments and controversies. Liver Int,2014,34:655-667.
[7] Reiberger T,Ferlitsch A,Payer BA,et al.Non-selective betabl-ocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.J Hepatol,2013,58:911-921.
[8] Kim JH,Kim JM,Cho YZ,et al.Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Clin Mol Hepatol,2014,20:376-383.
[9] Sersté T,Melot C,Francoz C,et al.Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology,2010,52:1017-1022.
[10] Shafiei MS,Lui S,Rockey DC.Integrin-linked kinase regulates endothelial cell nitric oxide synthase expression in hepatic sinusoidal endothelial cells. Liver Int,2015,35(4):1213-1221.
[11] Schwabl P,Hambruch E,Seeland BA,et al.The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.J Hepatol,2017,66(4):724-733.
[12] Vilaseca M,García-Calderó H,Lafoz E,et al.Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver Int,2017,37(7):1002-1012.
[13] Zheng L,Qin J,Sun L,et al.Intrahepatic upregulation of MRTF-A signaling contributes to increased hepatic vascular resistance in cirrhotic rats with portal hypertension. Clin Res Hepatol Gastroenterol,2017,41(3):303-310.
[14] Trebicka J,Hennenberg M,Laleman W,et al.Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology,2007,46(1):242-253.
[15] Matei V,Rodriguez-Vilarrupla A,Deulofeu R,et al.Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl₄ cirrhotic rats. J Hepatol,2008,49:192-197.
[16] Klein S,Rick J,Lehmann J,et al.Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut,2017,66(1):145-155.
[17] Rosado E,Rodriguez-Vilarrupla A,Gracia-Sancho J,et al.Terutr-oban,a TP-receptor antagonist,reduces portal pressure in cirrhotic rats. Hepatology,2013,58:1424-1435.
[18] Abraldes JG,Albillos A,Banares R,et al.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension:a randomized controlled trial. Gastroenterology,2009,136:1651-1658.
[19] Lim YL,Kim MY,Jang YO,et al.Rifaximin and propranolol combination therapy is more effective than propranolol monoth-erapy for the reduction of portal pressure:an open randomized controlled pilot study.Gut Liver,2017,11(5):702-710.
[20] Gupta N,Kumar A,Sharma P,et al.Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices:a randomized trial. Liver Int,2013,33(8):1148-1157.
[21] Manzano-Robleda Mdel C,Barranco-Fragoso B,Uribe M,et al. Portal vein thrombosis:what is new Ann Hepatol,2015,14(1):20-27.
[22] Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40:736-741.
[23] DeLeve LD,Valla DC,Garcia-Tsao G. Vascular disorders of the liver. Hepatology,2009,49(5):1729-1964.
[24] Plessier A,Darwish-Murad S,Hernandez-Guerra M,et al.Acute portal vein thrombosis unrelated to cirrhosis:a prospective multicenter follow-up study. Hepatology,2010,51(1):210-218.
[25] Condat B,Pessione F,Helene Denninger M,et al.Recent portal or mesenteric venous thrombosis:increased recognition and frequent recanalization on anticoagulant therapy. Hepatology,2000,32(3):466-470.
[26] Intagliata NM,Northup PG.Anticoagulant therapy in patients with cirrhosis. Semin Thromb Hemost,2015,41(5):514-519.
[27] Vilaseca M,García-Calderó H,Lafoz E,et al.The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology,2017,65(6):2031-2044.
[28] Cerini F,Vilaseca M,Lafoz E,et al.Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol,2016,64(4):834-842.
[29] Rossi J,Rouleau L,Tardif JC,et al.Effect of simvastatin on kruppel-like factor 2,endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress.Life Sci,2010,87(3-4):92-99.
[30] Pathak R,Shao L,Chafekar SM,et al.IKKβ regulates endothelial thrombomodulin in a Klf2-dependent manner.J Thromb Haemost,2014,12(9):1533-1544.
[31] Xu M,Xue W,Ma Z,et al.Resveratrol reduces the incidence of portal vein system thrombosis after splenectomy in a rat fibrosis model. Oxid Med Cell Longev,2016,7453849.
[32] Khatri A,Kanaparthy NS,Selvaraj BJ,et al.Primary Klebsiella pneumoniae osteomyelitis with bacteremia and sepsis in a patient with cirrhosis. Case Rep Infect Dis,2018,2018:3183805.
[33] Chung JW,Kim GH,Lee JH,et al.Safety,efficacy,and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis:a propensity score matching analysis. Clin Mol Hepatol,2014,20(4):384-391.
[34] Villa E,Cammà C,Marietta M,et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology,2012,143(5):1253-1260.

肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*

Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[6]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[7]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[10]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[11]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[14]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[15]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.